White Papers
Discover how Lab Virtual Assistants (LVA) powered by mcube™ are transforming research, development, and manufacturing labs into intelligent, self-optimizing environments.
Modern life-science labs are under growing pressure to accelerate research, scale efficiently, and maintain quality — but traditional manual workflows can’t keep up.
Quantifying the ROI of Integrated CDMO-CRO Models in Drug Development
As development costs climb and project timelines grow tighter, the traditional outsourcing model is showing its limitations. Fragmented coordination between CDMOs, CROs, and clinical supply vendors often leads to delays, inefficiencies, and lost opportunities.
Ultimate Guide to Pharmaceutical Quality Management
The guide highlights the essential shift in pharmaceutical quality management from document-centric to data-centric approaches, driven by the need to overcome unstructured data and siloed processes in a complex regulatory environment.
Benefit from Ecraid's Large Expertise Infrastructure for Efficient and High-quality ID research
Efficiency and quality in trials should never be a trade-off. Ecraid is the premier European academic network for infectious diseases and AMR, comprising over 1,200 clinical sites across 42 countries.
Step into the Future of ID Clinical Research alongside Ecraid
Traditional clinical trials are often too slow to respond to fast-moving infectious threats. Ecraid is changing that.
Better, faster small-molecule synthesis: leveraging modern tools to evaluate and optimize process chemistry
Better, faster small-molecule synthesis: leveraging modern tools to evaluate and optimize process chemistry
Precision in miniature: optimizing multiparticulate formulations for pediatric oncology
This white paper details a collaborative effort between Lonza’s Bend, OR site and Pfizer’s Groton, CT team to develop a robust commercial control strategy for a pediatric dosage form for crizotinib (Xalkori) in a material sparing fashion.
Bringing novel ADC formats into the clinic: Process development for antibody-oligonucleotide conjugates
Bioconjugates are no longer just for cancer therapies. This paper reveals how innovative advancements are opening up a new world of possibilities, from muscle disorders to inflammatory diseases.
ULTRUS ComplianceWire 2024 Benchmarking Study - Trends in Auditing and Supplier Management
Every year, UL Solutions conducts an anonymous benchmarking survey across its roughly 600 ULTRUS ComplianceWire customers, most of whom operate in the pharmaceutical and medical device sectors.
Unlock Faster, More Confident Biosimilar Development
Developing biosimilars requires rigorous analytical characterization to ensure safety, efficacy, and regulatory approval.
